International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 10 Issue: 02 | Feb - 2026 SJIF Rating: 8.659 ISSN: 2582-3930

Orphan Drugs in Treatment of Rare Disease: Advances in Drug Discovery, Regulatory Framework, Clinical Applications and Future Perspectives

Rahul D. Kamble[1], Anjali M. Kamble[2], Sneha A. Warang[3], Siddhi J. Munde

[1]*Assistant Professor, Department of Pharmaceutical Chemistry, Ashokrao Mane Institute of Pharmaceutical Sciences and Research, Save*

[2] *Student, Department of B. Pharmacy, Ashokrao Mane Institute of Pharmaceutical Sciences and Research, Save*

[3] *Student, Department of B. Pharmacy, Ashokrao Mane Institute of Pharmaceutical Sciences and Research, Save*

[4] Student, Department of B. Pharmacy, Ashokrao Mane Institute of Pharmaceutical Sciences and Research, Save

---***---

Abstract - Orphan drugs are medicinal products specifically developed for the diagnosis, prevention, or treatment of rare diseases, which collectively affect 300 to 400 million individuals worldwide. Rare diseases are defined by low prevalence, such as less than 200,000 patients in the US or less than 5 out of 10,000 people in the EU. Due to their small patient populations and the high cost of intensive research and development (R&D), these drugs are often commercially unattractive to the pharmaceutical industry.

Regulatory Frameworks and Incentives

To overcome commercial barriers and address the significant unmet medical need, global regulatory bodies have established incentive- driven frameworks. Key examples include:

United States: The Orphan Drug Act (ODA) of1983 provides incentives such as seven years of market exclusivity after approval, tax credits for clinical testing, and fee waivers.

European Union: The EU Orphan Regulation (2000) offers ten years of market exclusivity, protocol assistance, and fee waivers.

India: The New Drugs & Clinical Trial Regulations (2019) and the 2021 National Policy for Rare Diseases focus on expedited approval (within 90 days), possible local clinical trial waivers, and temporary price control exemptions.

Advances in Drug Discovery

Recent technological and scientific advancement are transforming the field

Genomics and Personalized Medicine: Many rare diseases have a genetic origin (~80%). Advances in genomics enable the development of personalized treatments that provide "the right patient with the right drug at the right dose at the right time"

Artificial Intelligence (AI): AI, Machine Learning (ML), and Deep Learning (DL) are vital tools for accelerating diagnosis, target identification, drug repurposing, and optimizing clinical trials.

Challenges and Future Directions

Despite the successes, several significant challenges persist: High Costs and Affordability: Orphan drugs often carry high prices, sometimes exceeding hundreds of thousands of dollars annually, straining health care systems

Global Inequity: Access to approved orphan treatments remains limited in many low- and middle-income countries (LMICs) due to a lack of structured reimbursement and market incentives.

Harmonization: Global harmonization is hindered by variations in rare disease definitions (e.g., US: <200,000; EU: <5/10,000; India: <500,000) and differing incentive packages.

Key Words: orphan drug, Genomics, Rare Disease, Hormonization,

1. INTRODUCTION

Only a small portion of the population is afflicted by rare diseases, sometimes referred to as orphan diseases.—defined as Less than200,000 patients in the US and less than5 out of10,000 people in the EU. Although each disease is uncommon, collectively there are over 7,000 recognized uncommon illnesses worldwide, impactingbetween300 and 400 million individuals worldwide. The majority of uncommon illnesses are chronic, progressive, and frequently life-threatening, with approximately 80% having a genetic origin. Due to their low prevalence, research and development of effective therapies have traditionally been limited, resulting in a high unmet medical need. To address this gap, the concept of orphan drugs emerged-medicinal goods created specifically for the diagnosis, avoidance, or therapy for uncommon illnesses. Despite the limited market potential and high development costs, orphan drugs are essential for enhancing illness, quality of life, and survival management for affected patients.

Over the past few decades, global regulatory bodies have introduced several incentive-driven frameworks, such as the EU Orphan Regulation and the United States Orphan Drug Act of 1983of 2000, and similar legislations in Japan and other regions. These policies encourage innovation by offering advantages including fee waivers, tax credits, market exclusivity, and grant support.

The growing scientific understanding of disease mechanisms, along with advances in genomics, molecular biology, and biopharmaceutical technologies, has significantly accelerated orphan drug discovery and development. As a result, an increasing number of orphan drugs are reaching the market, offering novel and effective therapies for previously untreatable rare conditions. The goal of this article is to give a thorough analysis of orphan drugs in the treatment of rare diseases, focusing on recent advances in drug discovery, the regulatory frameworks that promote their development, their clinical applications, and the future perspectives that will shape innovation and patient care in this rapidly evolving field.

2. OVERVIEW OF ORPHAN DRUG:

Orphan Drug: Definition and Concept:

An orphan drug refers to any medication created especially to diagnose, treat, or prevent are (orphan) disease an illness that only affects a tiny percentage of people. These illnesses are referred to as "orphan" because the pharmaceutical industry frequently ignores them due to their low market potential and high development costs, making them commercially unattractive. Despite limited profitability, orphan drugs address critical public health needs and are essential in helping individuals with uncommon diseases live better lives.

Developing an orphan drug is a major challenge for pharmaceutical firms, primarily due to intensive R&D, or research and development costs, limited patient populations, and lower turn on investment. To overcome these barriers, several countries have established orphan drug legislations offering incentives to encourage the development of such items, such as market exclusivity, tax rebates, fee reductions, and research grants.

Orphan Diseases:

Less than 5 in 10,000 people in the European Union and less than 200,000 people in the US suffer from orphan diseases, commonly referred to as uncommon diseases. Currently, an estimated 350 million people are afflicted by more than 7,000 known uncommon diseases people globally, with approximately 250 new rare diseases discovered each year. Around Eighty present of these disorders have a hereditary basis, caused by mutations in single or multiple genes, while others may result from infections, allergies, degenerative, or proliferative processes. Despite scientific progress, many of these diseases remain poorly understood and without effective treatments, making them a serious public health concern.

Orphan Drug Act:

In 1983, the United States passed the Orphan Drug Act (ODA), which was the first major legislative initiative to encourage the creation of orphan medications. The Act was established in reaction to the absence of adequate therapies for uncommon conditions like Huntington's illness, muscular dystrophy, and ALS. It provides a variety of rewards including seven years of tax credits and market exclusivity for clinical testing, and FDA awards—to promote innovation and reduce financial risk for developers. The U.S. FDA's Office of Orphan Product Development (OOPD) administers these programs and oversees orphan product designations.

Following the success of the ODA, similar frameworks were introduced globally, including in

The European Union (2000),Japan (1993), and Australia (1997). These regulations have collectively accelerated orphan drug research and made rare disease therapy development a priority in global health policy. However, countries with large populations such as China and India still lack comprehensive national orphan drug legislation, resulting in limited access to orphan medicines for millions of patients. In the European Union, Applications for orphan drug designation are assessed by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). This designation allows companies to receive benefits like lowering regulatory costs, scientific advice, and ten years of exclusivity in the market once the product is approved.

Key Characteristics of Orphan Drugs:

Orphan drugs possess several unique characteristics that distinguish them from conventional pharmaceutical products:

1.Small Patient Population:

Orphan medications are created to treat uncommon illnesses that impact a very limited number of individuals usually, less than 200,000 or less than 5 out of 10,000 individuals in the EU individuals in the U.S. Due to this small patient base, conducting large-scale studies or Generating significant market returns is often challenging.

High Development and Treatment Cost:

The cost of developing orphan drugs is substantially higher on a per-patient basis compared to common medications. This is primarily due to intensive research and development (R&D) expenses, limited production, and complex regulatory processes, coupled with low commercial profitability. Consequently, the Orphan medications are frequently quite expensive in order to compensate for the small market.

Limited Clinical Trial:

Due to the limited quantity of eligible Patients, clinical trials for orphan drugs usually involve smaller sample sizes, making it difficult to conduct large randomized controlled studies. As a result, regulatory authorities often allow flexible trial designs and adaptive approval pathways to ensure that these drugs reach patients faster while maintaining safety and efficacy standards.

Examples of Orphan Drugs:

1.Eculizumab

Fig.No.2.1 Eculizumab

Approved for a rare blood condition called paroxysmal nocturnal Haemoglobinuria (PNH)works by inhibiting complement-mediated red blood cell destruction.

2.Nusinersen-

Fig.No.2.2Nusinersen

The first approved therapy for SMA, or spinal muscular atrophy it enhances the production of survival motor neuron (SMN) protein, improving muscle function and survival in affected patients.

3.Advances in Drug Discovery for rare diseases:

The orphan drug discovery and regulatory framework is rapidly shifting toward the Ai, modelling, gene and cell therapies and adaptive evidence streams, while regulators (FDA, EMA) adopt flexible expedited pathways and post market evidence requirements. The rare disease remains a challenge for many countries. The recent methods for identifying and developing orphan therapeutics emphasize computational tools, translational modelling, and repurposing to shorten timelines and reduce cost. AI and machine learning approaches are being applied to target identification, biomarker discovery, drug repurposing and trial optimization or rare Diseases, and quantitative systems approaches are used to simulate heterogeneous patient populations and support dosing and trial design decisions. The regulatory agencies can facilitate the development and approval process by offering a variety of creative ways to address the aforementioned problems. Due to a number of factors, including drying pipelines, generic competition, patent expirations, and stricter regulations, the pharmaceutical industry's growth has slowed recently. Nearly 400 million people worldwide suffer from rare diseases, as their prevalence rises annually.

Since 1983, more than 600 treatments for orphan diseases have been approved and marketed in the US thanks to the Food and Drug Administration's (FDA) regulatory cooperation. 32 orphan-designated medications and biological products were approved by the FDA in 2020duetotheCOVID-19 pandemic, indicating further advancements in orphan drug research and development. The office of the Centre for Drug Evaluation and Research established a rare disease hub to evaluate marketing applications for specific rare diseases. In order to enable a rare disease policy, it worked with a rare disease team and received support and help. The recent methods for identifying and developing orphan therapeutics emphasize the computational tools, translational modelling and repurposing to shorten timelines and reduce cost. The most rare disease Despite significant advancements in research that have made it possible to comprehend their molecules fundamentally and legislation that offers financial and regulatory incentives to accelerate the development of particular medicines, there is currently no approved therapeutic option. A pharmaceutical company's ability to recover research and development costs is hampered by the small number of target patients who have the diseases of interest, which constitute a limited geographic area. A survey is conducted on disease models, such as animal models and induced pluripotent stem cells produced from patients. The function of biomarkers in clinical trials and medication development is explained.

Genomic & Personalized medicines:

Orphan drugs—drugs that treat diseases that plague small populations—and personalized medicine are comparable in many ways. In contrast to conventional "one-size-fits-most" therapies, it seeks to provide "the right patient with the right drug at the right dose at the right time." In the context of medications, it makes use of an individual's genomic and clinical information to select a drug and dose that maximizes efficacy and minimizes adverse events. "Salami slicing" is the technique by which personalized medicine divides each disease and its market into smaller subcategories. The orphan medications and tailored medicine treatments confront comparable difficulties. It is challenging to get adequate sample sizes for clinical effectiveness trials in a limited market. Additionally, there are few financial incentives to produce these medications due to the small market and low prices. However, permitting exorbitant medicine costs could prevent individuals in need of these treatments from accessing them. Payers may be able to leverage their experiences with orphan pharmaceuticals to inform pricing and reimbursement strategies for personalized medicine due to these parallels and the longer duration of orphan drugs on the market. This connection has not received much attention in the literature outside of editorials.

Many of the same issues that personalized medicine faces are frequently made worse by the additional expense and complexity of a "companion diagnostic, "which evaluates a much wider base population for therapy eligibility. In less than ten years, the number of approved customized medicine therapies and diagnostics in the US increased from 13 in 2006 to 113 in 2014 [13]. Prioritizing technology-driven biomedical advancements and building a million- person database to support future research were the goals of former President Osama's 2015 Precision Medicine Initiative [14]. The existing price and coverage strategy will need to be revised due to the growing significance of customized medicine and its financial implications. The ramifications of various price and coverage strategy option need to be clarified.

Drug Repurposing:

Repurposing existing medications that were previously approved for use in the market for a more prevalent disease has been a key component of drug development efforts for rare disorders. This is especially crucial because previously authorized substances will have already undergone pre-clinical toxicity testing and been judged to have shown pharmacological efficacy in a different disease indication. All 97 medications with an orphan designation that were previously approved for a more common indication are listed in data that the OOPD recently posted on the FDA website 29. The same source also lists the 71 medications that are classed as orphans and had previously been approved for use in treating another uncommon illness. Since they have overcome many of the obstacles that frequently cause attrition in the drug development process, all medications that have previously been approved for any illness indication by a regulatory body provide a substantial resource for research on rare diseases. More than 200 medications are currently classified as orphan pharmaceuticals and have been granted market authorization for certain illness indications. Of course, this is only a small portion of all approved medications that may be useful in treating uncommon diseases. Medication-centric, disease-centric, and target-centric are the three methods used in medication repurposing or repositioning research. The majority of pharmaceutical companies use a drug- centric strategy primarily to maximize profits and achieve optimal efficacy. However, a doctor would be more likely to prescribe medication form any disorders that have similar biological pathways, like cancer, inflammation, and autoimmune diseases. Every method aids in the discovery of new targets, which establishes new indications.

Biologics & Gene Therapy:

Gene therapy orphan medicinal products represent a unique class of innovative treatments. In the case of hereditary disorders, these therapies are often administered only once typically early in life with the goal of providing sufficient gene expression to achieve lifelong therapeutic benefit. However, the combination of a high one-time treatment cost and the need for lifelong clinical follow-up to evaluate safety and durability introduces a new set of scientific, financial, social, and ethical challenges for the pharmaceutical industry, regulatory agencies, and society. Given the exceptional characteristics and transformative potential of gene therapy, a three-point cooperative framework between the pharmaceutical industry and society has been proposed to promote sustainable development and equitable access to orphan gene therapies:

Transparent and Long-Term Collaboration:

A close, contractually defined partnership should be established between manufacturers and local healthcare stakeholders through transparent health technology assessments. This collaboration should ensure shared responsibility for the medical and scientific outcomes, shared financial risk, and joint participation in post-authorization clinical and regulatory development.

Fair Pricing and Risk-Sharing Models:

The stakeholders should agree upon locally affordable pricing that avoids the traditional high premiums often justified by the small patient populations in rare diseases. In cases of substantial manufacturing costs, companies should of extended payment models—spanning 15 to 20 years with instalment- based, risk-sharing mechanisms, recognizing the uncertainties surrounding long-term treatment outcomes. Society, in turn, should contribute by facilitating the establishment of patient registries, specialized treatment centres, and structured long-term follow-up programs, while also coordinating financial and administrative aspects of these agreements.

Artificial intelligence in rare disease drug development:

AI has become a vital tool in integrating and analysing complex biomedical data, supporting Diagnosing rare diseases (RDs) more quickly and accurately. Diagnostic decision support systems (DDSS) help clinicians by suggesting relevant differential diagnoses and have been effectively used for diseases like COVID-19 and various rare disorders. AIalgorithms can analyse patient registries, imaging, and genetic data to detect early disease patterns. For example, brain imaging and coulometer data have been used to predict disease onset in Huntington's disease, while machine learning (ML) has outperformed traditional tests in detecting pulmonary involvement in systemic sclerosis. Such applications enable earlier diagnosis, improved outcomes, and lower medical expenses. A branch of machine learning called deep learning (DL) is especially powerful for image-based diagnostics. It extracts meaningful features from high-dimensional data, improving accuracy and efficiency over traditional methods. Beyond diagnosis, AI accelerates drug development and discovery via determining therapeutic targets, repurposing already-approved medications, and optimizing clinical trials. Common algorithms like Support Vector Machines and Random Forests can process limited and complex data sets typical of rare diseases. Methods include high-throughput screening (HTS) and Quantitative Structure. Activity Relationship (QSAR) Modelling produce data for Auto design or repurpose drugs as seen with amyotrophic sclerosis. In summary, AI, ML, and DL are reshaping rare disease research by enhancing early detection, enabling precision medicine, and streamlining orphan drug discovery.

Regulatory Framework:

The field of drug development is heavily controlled. The same stringent requirements for proving safety and effectiveness apply to therapeutic alternatives for uncommon diseases as they do to more prevalent ones. Along with advancements in drug development, the Orphan Drug Act's approval in 1983 led to the use of real-world data, standardization of patient registries, and numerous additional resources for preclinical research, all of which have led to the approval of treatments for some of the most uncommon diseases. The development of gene therapies, which have the potential to significantly improve or even cure rare diseases in the near future, has been accelerated due to increased focus on diagnosis and treatment parties collaborating to determine the most appropriate research issue. Children are disproportionately affected by rare diseases, which have serious and incapacitating consequences. Patient communities, researchers, doctors, sponsors, and regulatory agencies are working together more and more to prevent the needless waste of data gathered in studies of these patients and to support effective drug development. Everyone is motivated and act fast to provide safe and efficient treatments. The most popular regulatory remedies that have been implemented to provide a framework for drug development in rare diseases are surveyed in this article.

A) United State: Orphan Substance Act 1983:

The 1983 Orphan Drug Act is a U.S. legislation that incentivizes pharmaceutical companies to develop drugs for uncommon illnesses by offering financial and market exclusivity incentives. A rare illness is defined as a single that affects less than 200,000 Americans or for whom the expense of development won't be recovered via sales. Key incentives incorporate tax breaks for medical research, a seven-year market exclusivity period and a waiver of user costs. The United States passed the Orphan Drug Act (ODA) in1983. Congress should encourage pharmaceutical firms to create medications for uncommon illnesses, for which there was previously



Fig.No4.1United State Regulatory Flow chart

Global Orphan Drug Regulations and Incentives:

India does not have a single "Orphan Drug Act" but regulates orphan drugs through 2019's New Drugs & Clinical Trial Regulations.

India: Orphan Substance Regulations & Incentives:

India has accelerated rare disease policy are form in recent years:

Regulatory definition: Orphan drugs are described as those treating conditions impacting less than500,000 Indians.

Expedited import and approval: As of April 2025, India's CDSCO has exempted orphan drugs from mandatory port testing, speeding up the import process. Importers must provide a legal undertaking and submit lab results within 15 days, reducing delays for high-cost, small- volume therapies.

Incentives: India provides expedited reviews, possible fee waivers, and national framework support for rare disease product inclusion. There is also an emphasis on support in orphan drug manufacturing.

Policy framework: The 2021 National Policy for Rare Diseases and Related CDSCO initiatives guide current incentives and encourage the establishment of more robust financial and R&D support (but India still lags behind the US/EU on tax credits and strong exclusivity guarantees).

Opportunities for Developers: India's evolving policies aim to simplify clinical trial requirements, promote public awareness, and strengthen procurement and IP protections for orphan drug makers.

Key Considerations:

India's regulatory environment is improving, with emphasis on speed and access rather than extensive market exclusivity or tax benefits as seen in the US/EU.

Global harmonization efforts through initiatives like IMDRF are on-going, aiming to streamline orphan drug incentives and regulatory approaches across nations.

Strong advocacy from patient groups continues to shape on-going reforms to improve orphan drug access in India.

India's orphan drug incentives, while less comprehensive than some Western markets, are progressively focused on reducing import and regulatory barriers, aligning with the global goal of fostering innovation and access for uncommon illnesses.

a) The Orphan Drug Act 1983-United States:

Before the ODA, most pharmaceutical companies focused on common diseases due to profitability. Rare diseases (affecting <200,000 individuals in the U.S.) were ―orphaned‖ because they offered little commercial return. The **1962 Kefauver–Harris Amendment** further increased R&D costs, worsening the **Global Orphan Drug Regulations and Incentives** act of rare diseases.

Key Incentives under the ODA:

Exclusive Market: 7 years of exclusivity for the specific indication after FDA approval.

Tax Credits: For eligible clinical research, upto50% costs (reduced to 25% in 2018).

Research Grants: Federal funding via the Office of Orphan Products Development

Fee Waivers: Exemption from for User Fees.

Regulatory Assistance: FDA guidance for trial design and development plans.

How It Works:

Designation: Developers request the classification of an orphan medication from the FDA.

a. Qualification: The medication needs to treat a rare disease (<200,000patients).

b. Incentives Granted: Once designated, the developer gains tax credits, user fee waivers, and market exclusivity.

c. Funding Support: Through the Orphan Product Grants Program.

FDA's Role:

Provides guidance, fast-track reviews, and expanded access programs.

Requires annual progress reports during development.

Can revoke exclusivity if the drug isn't adequately supplied.

B.EUROPEAN UNION:

EC Regulation No.141/2000: The EU adopted its Orphan medication framework in 2000, managed by The European Medicines Agency (EMA), to address similar market failures.

Eligibility Criteria:

Medical Need: Treats a continuously crippling or life-threatening illness.

Prevalence: impacts less than 5out of 10,000 EU citizens.

Unmet Need: There is currently no effective treatment or provides significant benefit.

Key Incentives:

Market Exclusivity:10 years post-approval (extendable by 2 years for a Paediatric Investigation Plan).

Protocol Assistance: Free/reduced-fee regulatory and scientific advice.

Fee Waivers: Reduced or waived EMA fees for SMEs.

Centralized Marketing Authorization: One approval valid across all EU Member States.

Funding & Grants: Access to EU research funding (e.g., *Horizon Europe*).

Conditional Approval: Early access in cases of urgent medical need.

Impact and Debates:

Success: Boosted rare disease drug development.

Concerns:

High drug prices train health care systems.

Salami slicing‖—sub dividing common diseases to qualify for orphan status. Focus skewed toward more prevalent rare diseases rather than ultra-rare ones. Calls for reform to make incentives more balanced.

C.JAPAN—ORPHAN DRUG SYSTEM (Established 1993)

The managed by the Ministry of Health of Labour and welfare (MHLW) and pharmaceuticals and Medical Devices Agency (PMDA)

Incentives:

Market Exclusivity: 10-year re-examination period.

Grants: Upto50% of R&D costs via the NIBIO stand for National Institute of Biomedical Innovation.

Tax Credits: For R and D expenses.

Priority Review & Consultation: Faster regulatory pathway and PMDA guidance.

PMDA's Role

Allows Japan's early participation in multinational trials (MRCTs).

Recently updated guidelines of Phase I studies in Japanese subjects are not always required, reducing delays.

Supports companiee, especially for start-ups, through clear consultation systems.

D.SOUTH KOREA-FRAMEWORK (2003)

- Supervised by the Food and Drug Safety Ministry (MFDS) and supported by the Korea Orphan and Essential Drug Centre (KODC).Incentives
- Market Exclusivity: 10years.
- Expedited Review : Fast-track for orphan drug applications.
- Fee Waivers: Reduced or waived application fees.
- Unique Feature: The KODC centrally manages import, supply, and distribution of orphan and essential drugs.

E)Australia—Orphan Drug Program (1997)

Administered by the Therapeutic Goods Administration (TGA)

- **Incentives**

i.Market Exclusivity: 5 years.

ii.Fee Waivers: Exemption from application and evaluation fees.

iii.Faster Review: Expedited process for orphan applications.

iv.Notable Aspect: Strong collaboration with the U.S.FDA, sharing regulatory data.

F)Canada—Emerging Framework

Historically lacked a formal orphan drug law but offered accelerated review and tax incentives.

Recent Development

National Strategy for Drugs for Rare Diseases (2023$1.5 billion spread over three years to increase affordability and accessibility across the country.

G) Other Notable Systems:

Country	Key Feature
Singapore	Simplified exemption policy; no exclusivity or funding yet.
Taiwan	Enacted orphan drug law in 2000, inspired by the U.S. and Japan.
China	Rapidly evolving framework to promote local R&D and rare disease registries.

H) India—CDSCO and National Policy for Rare Diseases (2021):

Orphan drug regulation is managed by the Drugs Controller General of India (DCGI) and the Central Drugs Standard Control Organization (CDSCO).

Key Provisions

Definition: Drugs for conditions affecting ≤500,000 people in India.

Expedited Approval: Applications processed within 90 days.

Trial Waivers: Local clinical trials may be waived if approved in major markets (U.S., EU, Japan, etc.).

Fee Exemptions: No fees for orphan drug trial applications.

Import Flexibility: Quick release at ports; testing results submitted with in15 days. Price Control: 5- year exemption from price regulation for new patented orphan drugs.

Post-Market Surveillance: Adjusted rules to ensure continued safety.

□GLOBAL HARMONIZATION CHALLENGES:

The global harmonization of regulations for orphan drugs faces significant challenges, stemming from differences in how countries define rare diseases, the varying incentives they provide for development and divergent requirements for clinical data and pricing. These inconsistencies can lead to delays in approval, limit patient access, and increase costs for pharmaceutical developers. The Various regulatory bodies, including the Central Drugs Standard Control Organization (CDSCO) in India, the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and the Pharmaceuticals and Medical Devices

Agency (PMDA) in Japan —operate with unique definitions and approval requirements. This leads to multiple obstacles for global drug developers. Rare diseases are not universally defined, which affects health drug can be granted orphan status:

U.S.: impacts less than 200,000 people.

E.U.: impacts less than 5 in 10,000 people. Japan: impacts less than 50,000 people. India: impacts less than500,000 people.

Differing incentive packages: The economic and procedural incentives vary by country and influence where companies prioritize development. The duration of market exclusivity, tax credits, and grants are not standardized globally.

Varied data requirements: Regulatory bodies have different requirements for the clinical data needed to demonstrate a medications effectiveness and safety Data from a trial in one area is not automatically accepted in another, often requiring trials.

Clinical trial and scientific difficulties:

The scientific challenges inherent in studying rare diseases are compounded by a fragmented regulatory landscape. Small patient populations: Limited patient numbers make large-scale clinical trials unfeasible. Trials are often smaller, multi-regional, and more complex in design. Harmonizing trial design and endpoints across countries with different standards and protocols is a significant challenge. Even within a single rare disease, genetic variations can cause different clinical presentations and treatment responses across populations. Clinical trials must account for this heterogeneity, which is difficult with small, geographically pools.

CLINICAL APPLICATIONS OF ORPHAN DRUGS:

Orphan drugs have transformed the treatment landscape for many previously untreatable rare diseases. Their development showcases how targeted therapies, gene technologies, and personalized medicine approaches can yield major clinical benefits despite small patient populations. Examples of Successful Orphan Drugs and Their Impact

1.CF or cystic fibrosis:

Cystic fibrosis is a hereditary condition that results in thick mucus build-up in the lungs and digestive tract due to abnormalities in the CFTR gene. The introduction of Invocator and Lumacaft or has revolutionized CF management.

Invocator acts as a CFTR potentiate, improving chloride transport across cell membranes and enhancing lung function.

Lumacaftor, often combined with Invocator, helps correct them is filed CFTR protein, addressing the underlying cause of the disease.

Together, these therapies have increased CF patients 'life expectancy and enhanced their quality of life.

2.Spinal Muscular Atrophy (SMA):

SMA is a severe neuromuscular disorder caused by mutations in the SMN1 gene, leading to progressive muscle weakness.

Nusinersen (Spinraza) is an antisense oligonucleotide that modifies SMN2 gene splicing to increase production of functional SMN protein. It has shown remarkable improvements in motor function and survival, especially when treatment starts early.

Zolgensma is a one-time gene therapy that delivers a functional copy of the SMN1 gene using an adeno-associated viral vector (AAV9). It provides long-term benefit from a single infusion and represents one of the most successful examples of gene therapy for rare disease.

3.Oncology (Chronic Myeloid Leukemia–CML):

Before the development of targeted therapies, CML was often fatal. Imatinib (Gleevec), a selective tyrosine kinase inhibitor, was the first targeted cancer therapy to achieve high efficacy with minimal toxicity. By inhibiting the abnormal BCR-ABL fusion protein responsible for CML, Imagine transformed the disease from a terminal cancer into a manageable chronic condition. Its success paved the way for precision medicine approaches in oncology and beyond.

4.Metabolic Disorders:

Enzyme replacement therapies (ERTs) have proven effective for several inborn errors of metabolism, where patients lack specific enzymes needed to break down metabolic substrates.

For example, Imiglucerase for Gaucher's disease and Agalsidase beta for Fabry disease supply functional enzymes to restore metabolic balance, reducing organ damage and improving survival.

Although lifelong and expensive, ERTs demonstrate how biotechnological advances can successfully treat previously fatal disorders.

Challenges in Rare Disease Clinical Trials:

Despite these successes, the development of orphan drugs faces multiple challenges:

1.Small Patient Populations:

Recruiting adequate participants is difficult because rare diseases affect very few people worldwide. This limits statistical power and often requires innovative trial designs, such as adaptive or single-arm studies, and real-world evidence.

Ethical Considerations:

In life-threatening conditions without existing treatments, placebo-controlled trials may be considered unethical. Researchers must balance scientific rigor with compassionate access, sometimes using historical controls or cross over designs to ensure fairness.

2.High Development Costs:

Due to the limited market size, companies face challenges in recovering research and development costs. Manufacturing biologics and gene therapies is complex and expensive, and pricing models often spark ethical and economic debates about accessibility and affordability.

3.Regulatory and Logistical Barriers:

Rare diseases often require tailored regulatory pathways and special incentives Agencies like the FDA and EMA have established expedited programs (e.g., orphan drug designation, accelerated approval, and break through therapy status) to support these developments.

4.Data Scarcity:

Limited clinical and biological data make it difficult to understand disease progression and Identify meaningful end points. AI and computational modeling are now helping overcome these barriers by simulating patient outcomes and supporting trial design.

□CHALLENGES IN ORPHAN DRUG DEVELOPMENT:

Despite significant policy support and scientific advances, the development of orphan drugs faces numerous economic, regulatory, and ethical challenges that limit accessibility and sustainability worldwide.

1 .High Cost of Therapy and Affordability Issues:

Orphan drugs often carry extremely high price tags — in some cases exceeding each patient costs hundreds of thousands of dollars annually. This stems from high R&D costs, complex manufacturing, and the small patient populations that limit revenue recovery. While incentives like market exclusivity help developers, the resulting monopoly pricing creates major affordability barriers for patients and health care systems.

2. Limited Market Incentives in Low-and Middle-Income Countries (LMICs):

Most orphan drug incentive frameworks exist in high-income regions like the United States, the European Union, and Japan. In contrast, LMICs lack structured reimbursement systems, making rare disease therapies financially unviable for companies to market. As a result, geographical inequities persist, and many patients in developing countries have no access to approved orphan treatments.

3. Access and Equity Gaps

: Even in regions with established orphan drug policies, access remains in consistent due to Variable nationalreimbursement policies, budget constraints, and limited diagnostic capabilities. Delayed inclusion national formularies further restricts treatment availability, contributing to health inequity among rare disease patients globally.

4. Lack of Long-Term Safety and Efficacy Data:

Because of small clinical trial populations and accelerated approval pathways, many orphan drugs enter the market with limited long-term data. Post-marketing surveillance is critical but often under-resourced, leading to uncertainty about durability of response, late-emerging side effects, and real-world effectiveness. This is particularly concerning for gene and cell therapy.

5. Manufacturing and Supply Chain Complexities:

The production of orphan drugs — especially biologics and gene therapies — involves highly specialized, small-scale manufacturing processes. Maintaining quality, stability, and global supply is logistically challenging and costly. Moreover, disruptions in the supply chain can lead to drug shortages, affecting vulnerable patient groups on continuous therapy.

□FUTURE PERSPECTIVE:

The prospects for orphan drug development are being transformed by technological innovation, global policy expansion, and collaborative research models. Continued integration of genomics, artificial intelligence, and real-world evidence (RWE) is expected to accelerate therapeutic breakthroughs and facilitate individuals with uncommon illnesses' access.

1 .Advances in Gene and Cell Therapies:

Recent breakthroughs in gene editing (e.g., CRISPR-Cas9), mRNA technology, and cell- based therapies are transforming treatment possibilities for genetic and metabolic rare diseases. These innovations offer the potential for curative, one-time treatments, addressing the root cause of disease rather than symptoms.

However, challenges remain in ensuring long-term safety, scalable manufacturing, and affordability. Future progress will depend on developing cost-effective production platforms and global data-sharing systems to monitor outcomes over time.

2. Expansion of Orphan Drug Policies in Developing Nations

Developing countries such as India, China, and South Korea are introducing or strengthening orphan drug regulations to promote local innovation and access. These frameworks are inspired by models from the U.S. FDA and EMA, offering incentives like tax benefits, fee waivers, and expedited approvals.

Future policies are expected to focus on price control mechanisms, public funding, and regional collaborations to ensure equitable access in low- and middle-income countries (LMICs).

3. Use of Empirical Data (RWE) and Big Data

RWE is increasingly being used in post-market surveillance, patient registries, and electronic health records. Revolutionizing rare disease research. Big data analytics and AI-driven models can uncover disease patterns, assess treatment efficacy, and refine regulatory decision- making.

Regulatory agencies such as the FDA and EMA are increasingly accepting RWE to the complement traditional clinical trials, particularly for ultra-rare conditions with limited patient data. Precision Medicine and Personalized Orphan Drug Development

Advances in genomic sequencing and molecular diagnostics are enabling the development of personalized orphan treatments based on a person's genetic composition. This approach — delivering —the right drug to the right patient at the right dose‖ — is narrowing the gap between common and rare disease research.

4. Public–Private Partnerships and Affordability:

To address affordability and access challenges, public–private partnerships (PPPs) are emerging as crucial enablers of sustainable orphan drug development. Collaborative models between governments, academia, non-profits, and the pharmaceutical industry can: Share research and financial risks.

Support patient registries and long-term data collection.

Implement risk-sharing payment models such as outcome-based reimbursement or installment payments.

Such partnerships can help balance innovation with equitable access, ensuring that life-saving therapies reach all patients in need.

CONCLUSION:

The field of orphan drugs has evolved into one of the most dynamic and impactful areas of modern medicine, offering new hope to millions affected by rare diseases worldwide. Driven by advances in genomics, artificial intelligence, and biotechnological innovation, the discovery and development of therapies for previously untreatable conditions have accelerated significantly.

Regulatory bodies including CDSCO, PMDA, EMA, and the FDA have played a pivotal role in creating flexible and expedited approval pathways, promoting innovation through incentives, and supporting post-marketing surveillance to ensure safety and efficacy. Despite these advancements, challenges like high development expenses, a small number of patients and in equitable global access continue to hinder progress.

Emerging approaches — including gene and cell therapies, AI-driven drug discovery, and real-world evidence integration — promise to redefine the landscape of orphan drug development. Furthermore, public–private partnerships, expanded policy support in developing nations, and risk-sharing financial models are paving the way toward greater accessibility and sustainability.

In essence, the future of orphan drug development lies in a collaborative, technology-driven, and patient-centered ecosystem. By uniting scientific innovation, regulatory flexibility, and global cooperation, the vision of delivering effective, affordable, and personalized therapies.

ACKNOWLEDGEMENT

We gratefully recognize the contributions of global regulatory and research organizations including the U.S. Food and Drug Administration, European Medicines Agency, Central Drugs Standard Control Organization, and Pharmaceuticals and Medical Devices Agency, whose guidelines, regulatory frameworks, and publicly available reports provided valuable reference material for this review.

Finally, we sincerely thank all researchers, authors, and institutions whose published work on orphan drugs and rare diseases has contributed significantly to the development of this article.

REFERENCES

1. Yoo, H.-W. Development of orphan drugs for rare diseases. Clan Expo Podiatry. 2024; 67(7):315–327. DOI:10.3345/cep.2023.00535.E-CEP
2. He, D., Wang, R., Xu, Z. L. etal. The use of artificial intelligence in the treatment of rare diseases: A scoping review. Intractable & Rare Diseases Research. 2024;13(1):12–22. DOI:10.5582/irdr.2023.01111.IRDR Journal+2J-STAGE+2
3. Essendon, H., Armijo, N., Vargas, C. et al. Challenges for gene therapy in the financial sustainability of health systems: a scoping review. Orphaned J Rare Dis. 2024;19:243. DOI:10.1186/s13023-024-03249-z. BiomedCentral
4. Insert, A. Report lauds Orphan Drug Act but notes most therapies are blocked from competition. AJMC. 2021 Mar 28. AJMC

5. Rogers, H.-A. & Sheikh, H. Z. The Orphan Drug Act: Legal Overview and Policy Considerations. Congressional Research Service Report NoIF12605.2024. Congress

6. Goyal, V. K., Goudanavar, P. S., Elangoli, S., & Saj, A. Orphan Drugs Overview and Regulatory review procedure. International Journal of Drug Regulatory Affairs. 2024;11(2). DOI:10.22270/ijdra.v11i2.609.IJDRA

7. National Academies Press. Rare Diseases and Orphan Products: Accelerating Research and Development. InstituteofMedicine;2010.AppendixB:―Innovation and the Orphan Drug Act, 1983-2009: Regulatory and Clinical Characteristics of Approved Orphan Drugs.‖ nap.nationalacademies.org

8. Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A. et al. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. arXivpreprint.2022.arxiv.org

9. Indian Organization for Rare Diseases (IORD) is an umbrella organization, representing interests of all rare disease patients, patient support groups, health policy advocates and health care providers extending support or working in the field of any of the under mentioned rare disease groups.

10. Alessandrini, M. Preynat-Seauve,O., Briun,K.D., and Pepper,M.S.(2019).Stemcell Therapy for neurological disorders.South Afr. Med. J.=Suid-Afrikaansetydskrif vir geneeskunde109,70–77.doi:10.7196/SAMJ.2019.v109i8b.14009.

11. Kimmel L, Conti RM, Volerman A, Chua KP. Pediatric orphan drug indications: 2010- 2018. Pediatrics. 2020;145:e20193128. doi:10.1542/peds.2019-3128.[DOI] [PMC free article] [PubMed] [GoogleScholar]

12. Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare diseases in Hong Kong - adopting ORPHA codes in ICD-10 based healthcare administrative datasets. Orphanet JRare Dis. 2018;13:147.doi: 10.1186/s13023-018-0892-5

13. KrawitzPM.Artificial intelligence in the diagnosis of rare disorders: the development of Phenotypenalysis analysis. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2022; **65**(11): 1159-1163.

14. Choudhury,M.C.,Saberwal,G.,2021,Raredisease researchanddevelopmentinIndia: present status and future prospects. Journal of Genetic Engineering and Biotechnology, 19(1), 49.

15. A comparative analysis of how India, the U.S., and the EU approach rare disease regulation, highlighting challenges and innovations across regions.

16. The Orphan Drug Act. Implementation and Impact. United States Department of Health and Human Services. Office of E.Seoane-Vazquezetal. Incentives for orphan drug research and development in the United States Orphanet Journal of Rare Diseases (2008)

17. Sakushima, K., Takeda, H. & Aoi, Y. Orphan drug designation and development in Japan: 25years of experience and assessment.Nat.Rev.DrugDiscov.20,893–894(2021).

18. Orphan Drug Program. Therapeutic Goods Administration (Australia), 1998. http://www.health.gov/au.tga.

19. Pryde DC, Groft SC. Definitions, history and regulatory framework for rare diseases and orphan drugs. In: Pryde DC, Groft SC, editors. Orphan Drugs and Rare Diseases. England; RSC Drug DiscovSer. 2014;38:3–31. https://doi.org/10.1039/9781782624202-00003

20. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical trials in small population [Internet]. European Medicines Agency. United Kingdom: European Medicines Agency; 2006[cited 2023May 24].